I won’t unduly belabor the point, but this is increasingly the new multi-national model for new drug pricing (Keytruda® pricing being a rather pointed example): often rather steep discounts from US list prices.
Even as to truly revolutionary treatments, the world’s governmental-affiliated payers will increasingly seek — and win — price concessions from big pharma. And Mr. Frazier is (smartly, I think, given the incoming Administration is also likely to target drug pricing) talking peace, on price increases, more generally.
Here is the overnight item — you may read it for yourself. But it was all easily predictable, back from June to October 2016.
So, to quote the old adage: “We’ve established what they are — now we are simply haggling over. . . price.” [But it used to refer primarily to investment bankers.] That was uncalled for. Now stricken.